Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AMG 199 in MUC17-positive advanced solid tumors
NL-OMON56431Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amg 199 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer (CRC) and 1 more, sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 2 more. Started Dec 2020; status: completed.
02
Drugs
amg 199
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON56431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56431.